^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ewing Sarcoma |
| Regimen: | VIDE (doxorubicin hydrochloride + etoposide IV + ifosfamide + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/19/2020
Excerpt:
Ewing sarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy)…Other Recommended Regimens…VIDE (vincristine, ifosfamide, doxorubicin, and etoposide)
